Digital Edition: MedTech Strategist October 2022, vol. 9 #9

article image
ARTICLE SUMMARY:

AI-based guidance and mapping technologies promise safer, more personalized treatments for prostate cancer. AI is impacting dermatology too: we track Pathology Watch's journey from AI developer to CLIA-certified digital path lab. Robocath is moving digital surgery from the OR into the cath lab; hospitals face major revenue declines as outpatient procedures shift offsite. Plus new solutions for blood collection, Pacertool's new biomarker for HF, and profiles of Precisis and Qnovia.

×

This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: